Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

122
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
122
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

57
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

131
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
131
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

273
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
273
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

327
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial.

Hepatology (Baltimore, Md.)·2026
Same author

Addressing current limitations of colonoscopy for colorectal cancer screening.

Expert review of gastroenterology & hepatology·2026
Same author

Steroid therapy is linked to lower incidence of acute kidney injury in patients with severe alcohol-associated hepatitis.

Scientific reports·2025
Same author

Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Larsucosterol for the Treatment of Alcohol-Associated Hepatitis.

NEJM evidence·2025
Same author

Effects of COVID-19 virus-like particles on the behavioral and cognitive performance of human apolipoprotein E targeted replacement mice.

Frontiers in immunology·2024

Related Experiment Video

Updated: Mar 18, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.2K

Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update.

Eric Yoon1, Arooj Babar1, Moaz Choudhary1

  • 1Rutgers New Jersey Medical School, University Hospital, Newark, New Jersey, USA.

Journal of Clinical and Translational Hepatology
|June 29, 2016
PubMed
Summary

Acetaminophen (APAP) overdose causes significant liver injury and failure, a major cause of liver transplants. Further research into molecular pathways is needed for better treatments beyond N-acetylcysteine therapy.

Keywords:
APAPAcetaminophen toxicityAcute liver failure (ALF)HepatotoxicityParacetamol

More Related Videos

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
05:37

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration

Published on: May 31, 2018

12.9K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.5K

Related Experiment Videos

Last Updated: Mar 18, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.2K
Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
05:37

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration

Published on: May 31, 2018

12.9K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.5K

Area of Science:

  • Hepatology
  • Toxicology
  • Biochemistry

Background:

  • Acetaminophen (APAP) overdose is a leading cause of acute liver failure (ALF) in the US.
  • APAP hepatotoxicity involves hepatic microsomal metabolic pathways.
  • It accounts for over 50% of overdose-related ALF and 20% of liver transplants.

Purpose of the Study:

  • To elucidate the pathophysiology, disease course, and management of APAP-induced ALF.
  • To identify areas for future research in APAP hepatotoxicity.
  • To improve patient outcomes and reduce mortality associated with APAP overdose.

Main Methods:

  • Review of existing literature on APAP hepatotoxicity.
  • Analysis of clinical presentation and outcomes.
  • Discussion of current and potential therapeutic strategies.

Main Results:

  • APAP hepatotoxicity follows a predictable timeline but has variable clinical presentations.
  • N-acetylcysteine (NAC) is the primary antidote.
  • Liver transplantation is a life-saving option for select patients.

Conclusions:

  • Understanding APAP hepatotoxicity requires further elucidation of its molecular mechanisms.
  • Future research should focus on molecular signaling pathways for novel antidotal strategies.
  • Improved understanding may lead to reduced morbidity and mortality from APAP overdose.